Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG.

Integr Biol (Camb). 2011 Apr;3(4):375-87. doi: 10.1039/c0ib00135j. Epub 2011 Feb 14.

2.

Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.

Ji YT, Liu YN, Liu ZP.

Curr Med Chem. 2015;22(11):1348-60. Review.

PMID:
25620094
3.

[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].

Cai YC, Zou Y, Xian LJ.

Yao Xue Xue Bao. 2010 Mar;45(3):283-8. Review. Chinese.

PMID:
21351502
4.

Recent advances in vascular disrupting agents in cancer therapy.

Porcù E, Bortolozzi R, Basso G, Viola G.

Future Med Chem. 2014 Sep;6(13):1485-98. doi: 10.4155/fmc.14.104. Review.

PMID:
25365233
5.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
6.

Combination of vascular disrupting agents and ionizing radiation.

Clémenson C, Chargari C, Deutsch E.

Crit Rev Oncol Hematol. 2013 May;86(2):143-60. doi: 10.1016/j.critrevonc.2012.10.002. Epub 2012 Nov 20. Review.

PMID:
23177097
7.

Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

Spear MA, LoRusso P, Mita A, Mita M.

Curr Drug Targets. 2011 Dec;12(14):2009-15. Review.

PMID:
21777190
8.

Vascular disrupting agents in clinical development.

Hinnen P, Eskens FA.

Br J Cancer. 2007 Apr 23;96(8):1159-65. Epub 2007 Mar 20. Review.

9.

Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.

Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC.

Nat Clin Pract Oncol. 2006 Dec;3(12):682-92. Review.

PMID:
17139319
10.

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Kanthou C, Tozer GM.

Int J Exp Pathol. 2009 Jun;90(3):284-94. doi: 10.1111/j.1365-2613.2009.00651.x. Review.

11.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
12.

Vascular disrupting agents: a new class of drug in cancer therapy.

Gaya AM, Rustin GJ.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):277-90. Review.

PMID:
15997924
13.

Small molecule vascular disrupting agents: potential new drugs for cancer treatment.

Cai SX.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. Review.

PMID:
18221055
14.

Tumour vascular disrupting agents: combating treatment resistance.

Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA.

Br J Radiol. 2008 Oct;81 Spec No 1:S12-20. doi: 10.1259/bjr/36205483. Review.

PMID:
18819993
15.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

16.

Vascular disrupting agents (VDAs) in anticancer therapy.

Daenen LG, Roodhart JM, Shaked Y, Voest EE.

Curr Clin Pharmacol. 2010 Aug;5(3):178-85. Review.

PMID:
20406172
17.

Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.

Banerjee S, Hwang DJ, Li W, Miller DD.

Molecules. 2016 Nov 2;21(11). pii: E1468. Review.

18.

Vascular-disrupting agents in oncology.

Mita MM, Sargsyan L, Mita AC, Spear M.

Expert Opin Investig Drugs. 2013 Mar;22(3):317-28. doi: 10.1517/13543784.2013.759557. Epub 2013 Jan 15. Review.

PMID:
23316880
19.

Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Baguley BC, Siemann DW.

Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Review.

20.

Vascular damaging agents.

Patterson DM, Rustin GJ.

Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56. Epub 2007 Apr 24. Review.

PMID:
17459681

Supplemental Content

Support Center